Le syndrome de détresse respiratoire aiguë (SDRA) est caractérisé par des lésions alvéolaires diffuses menant à un œdème alvéolaire lésionnel et une insuffisance respiratoire aiguë hypoxémique. Malgré les progrès récents dans la prise en charge des patients de réanimation, le SDRA reste un syndrome fréquent et associé à une morbimortalité importante. Deux mécanismes principaux du SDRA semblent associés à une mortalité plus élevée et à des réponses thérapeutiques différentes : la déficience de la clairance liquidienne alvéolaire (AFC, pour alveolar fluid clearance), l’incapacité pour l’épithélium alvéolaire de résorber l’œdème alvéolaire, et la présence d’un phénotype « hyper-inflammatoire ». Les approches pharmacologiques du traitement du SDRA restent limitées et il est nécessaire de poursuivre l’étude des voies biologiques impliquées dans la pathogénie du SDRA et dans sa résolution afin de développer des approches innovantes des prises en charge diagnostique et thérapeutique du SDRA. RAGE, le récepteur des produits de glycation avancée, est un récepteur multi-ligands, exprimé abondamment par les cellules épithéliales alvéolaires du poumon (pneumocytes), qui module de nombreuses voies de signalisation intracellulaire. De nombreuses études récentes suggèrent que sRAGE, la forme soluble principale de RAGE, pourrait servir de marqueur lésionnel du pneumocyte de type I, et que RAGE pourrait jouer un rôle-pivot dans la pathophysiologie du SDRA, en initiant et en entretenant la réponse inflammatoire alvéolaire. Nos objectifs étaient de caractériser les rôles de RAGE au cours du SDRA, grâce à une approche translationnelle combinant études cliniques et précliniques. D’abord, des études cliniques observationnelles et interventionnelles ont été conduites afin de caractériser sRAGE comme un véritable biomarqueur dans le SDRA. Ensuite, des cultures in vitro de cellules épithéliales et de macrophages, ainsi qu’un modèle expérimental in vivo de SDRA murin par instillation trachéale d’acide chlorhydrique ont été utilisés pour décrire les effets de la voie RAGE sur les mécanismes d’AFC et l’inflammation macrophagique médiée par l’inflammasome « Nod-Like Receptor family, Pyrin domain containing 3 » (NLRP3). Enfin, l’effet d’une inhibition de RAGE, par sRAGE recombinant ou par anticorps monoclonal anti-RAGE, était testée en modèle murin. Nos résultats issus des études cliniques suggèrent que sRAGE présente toutes les caractéristiques d’un biomarqueur au cours du SDRA, avec un intérêt dans le diagnostic, le pronostic et la prédiction du risque de développer un SDRA dans une population à risque. Pris ensemble, notre travail suggère que la voie RAGE joue un rôle important dans la régulation de l’atteinte pulmonaire, de l’AFC et de l’activation macrophagique au cours du SDRA. Toutefois, les mécanismes précis de cette régulation restent incertains. La forme soluble de RAGE (sRAGE), lorsqu’elle est dosée dans le plasma, présente toutes les caractéristiques d’un biomarqueur pouvant être utile en pratique clinique, mais son intérêt dans la sélection de sous-groupes (ou « phénotypes ») de patients pouvant bénéficier de traitements ciblés reste à étudier. La voie RAGE pourrait enfin représenter une cible thérapeutique prometteuse. Bien que des études de validation restent nécessaires, ces résultats pourraient ouvrir de nouvelles perspectives dans la prise en charge des patients atteints de SDRA. / The acute respiratory distress syndrome (ARDS) is associated with diffuse alveolarinjury leading to increased permeability pulmonary edema and hypoxemic respiratory failure. Despite recent improvements in intensive care, ARDS is still frequent and associated with high mortality and morbidity. Two major features of ARDS may contribute to mortality and response to treatment: impaired alveolar fluid clearance (AFC), i.e. altered capacity of the alveolar epithelium to remove edema fluid from distal lung airspaces, and phenotypes of severe inflammation. Pharmacological approaches of ARDS treatment are limited and further mechanistic explorations are needed to develop innovative diagnostic and therapeutic approaches. The receptor for advanced glycation endproducts (RAGE) is a multiligand pattern recognition receptor that is abundantly expressed by lung alveolar epithelial cells andmodulates several cellular signaling pathways. There is growing evidence supporting sRAGE (the main soluble isoform of RAGE) as a marker of epithelial cell injury, and RAGE may be pivotal in ARDS pathophysiology through the initiation and perpetuation of inflammatory responses. Our objectives were to characterize the roles of RAGE in ARDS through a translational approach combining preclinical and clinical studies. First, observational and interventional clinical studies were conducted to test sRAGE as a biomarker during ARDS.Then, cultures of epithelial cells, macrophages and a mouse model of acidinduced lung injury were used to describe the effects of RAGE pathway on AFC and inflammation, with special emphasis on a macrophage activation through NodLikeReceptor family, Pyrindomain containing 3 (NLRP3) inflammasome. Acidinjured mice were treated with an antiRAGE monoclonal antibody or recombinant sRAGE to test the impact of RAGE inhibition on criteria of experimental ARDS. Results from clinical studies support a role of sRAGE as a biomarker of ARDS, withdiagnostic, prognostic and predictive values. In addition, plasma sRAGE is correlated with a lung imaging phenotype of nonfocal ARDS and could inform on therapeutic response. Herein, we also describe in vivo and in vitro effects of RAGE activation on transepithelial fluid transport and expression levels of epithelial channels (aquaporin 5, αNa,KATPaseandαENaC) and on macrophage activation through NLRP3 inflammasome. Finally, RAGE inhibition improves AFC and decreases lung injury in vivo. Taken together, our findings support a role of RAGE pathway in the regulation of lung injury, AFC and macrophage activation during ARDS, albeit precise regulatory mechanisms remain uncertain. sRAGE has most features of a validated biomarker that could be used in clinical medicine, but whether it may help to identify subgroups (or phenotypes) of patients that would benefit from tailored therapy remains underinvestigated. Modulation ofRAGE pathway may be a promising therapeutic target, and though validation studies are warranted, such findings may ultimately open novel diagnostic and therapeutic perspectivesin patients with ARDS.

No description available.

Homeostase do O2 é essencial para a sobrevivência e desenvolvimento fisiológico dos organismos. A falta de O2 nos tecidos é um fator subjacente comum na morbidade e mortalidade de situações clínicas como na Síndrome do Desconforto Respiratório Agudo (ARDS). Na retomada da homeostase as células mielóides exercem suas funções especializadas nas áreas de hipóxia. A adaptação destas células nesta condição depende dos produtos do gene HIF-1<font face=\"Symbol\">&#945, fator de transcrição que responde às mudanças de O2. Neste trabalho caracterizamos os mecanismos celulares e moleculares operantes no estado de hipóxia em resposta à reação inflamatória aguda no pulmão induzida pela I/R ateria mesentérica em duas linhagens de camundongos geneticamente selecionadas para máxima (AIRmax) ou mínima (AIRmin) Resposta Inflamatória Aguda (AIR). Observamos uma alta reação inflamatória aguda em resposta a I/R. Altos níveis de expressão dos genes envolvidos em situações de hipóxia Hif-1<font face=\"Symbol\">&#945, Vhl e das citocinas Il-1<font face=\"Symbol\">&#946 e Il-6 mostraram-se relacionados com a alta AIR nos camundongos AIRmax. / Oxygen homeostasis is essential for survival and physiologic development of organisms. Lack of O2 in tissues is a common underlying factor in morbidity and mortality for numerous serious medical conditions such as the Acute Respiratory Distress Syndrome (ARDS). For homeostasis recovery the myeloid cells exert their functions in specialized areas of hypoxia. The adaptation of myeloid cells in low O2 tissue depends on the HIF-1<font face=\"Symbol\">&#945 gene products. Hif-1<font face=\"Symbol\">&#945 is a transcription factor that responds to O2 levels change. In this study we characterize, in two lines of mice selected for maximal (AIRmax) or minimal (AIRmin) Acute Inflammatory response (AIR), the cellular and molecular mechanisms operating in the hypoxia state during an acute inflammatory reaction in the lung parenchyma produced by mesenteric artery Ischemia. We observed an acute inflammatory reaction with high levels of Hif-1<font face=\"Symbol\">&#945 and Vhl genes expression involved in hypoxia conditions and IL-1<font face=\"Symbol\">&#946 and IL-6 genes showed related to high AIR in AIRmax mice.

In experimental acute respiratory distress syndrome (ARDS), random variation of tidal volumes (VT ) during volume controlled ventilation improves gas exchange and respiratory system mechanics (so-called stochastic resonance hypothesis). It is unknown whether those positive effects may be further enhanced by periodic VT fluctuation at distinct frequencies, also known as deterministic frequency resonance.We hypothesized that the positive effects of variable ventilation on lung functionmay be further amplified by periodic VT fluctuation at specific frequencies. In anesthetized and mechanically ventilated pigs, severe ARDS was induced by saline lung lavage and injurious VT (double-hit model). Animals were then randomly assigned to 6 h of protective ventilation with one of four VT patterns: (1) random variation of VT (WN); (2) P04, main VT frequency of 0.13Hz; (3) P10, main VT frequency of 0.05Hz; (4) VCV, conventional non-variable volume controlled ventilation. In groups with variable VT , the coefficient of variation was identical (30%). We assessed lung mechanics and gas exchange, and determined lung histology and inflammation. Compared to VCV, WN, P04, and P10 resulted in lower respiratory system elastance (63 ± 13 cm H2O/L vs. 50 ± 14 cm H2O/L, 48.4 ± 21 cm H2O/L, and 45.1 ± 5.9 cm H2O/L respectively, P < 0.05 all), but only P10 improved PaO2/FIO2 after 6 h of ventilation (318 ± 96 vs. 445 ± 110mm Hg, P < 0.05). Cycle-by-cycle analysis of lung mechanics suggested intertidal recruitment/de-recruitment in P10. Lung histologic damage and inflammation did not differ among groups. In this experimental model of severe ARDS, periodic VT fluctuation at a frequency of 0.05Hz improved oxygenation during variable ventilation, suggesting that deterministic resonance adds further benefit to variable ventilation.

<p><strong>Background</strong>: Human rhinovirus/enterovirus (HRV/ENT) infections are commonly identified in children with acute respiratory infections (ARIs), but data on their clinical severity remains limited. We compared the clinical severity of HRV/ENT to respiratory syncytial virus (RSV), influenza A/B (FLU) and other common respiratory virus in children.</p> <p><strong>Methods</strong>: Retrospective study of children with ARIs and confirmed single positive viral infections on mid-turbinate swabs by molecular assays. Outcome measures included hospital admission and, for inpatients, a composite end-point consisting of intensive care admission, hospitalization greater than 5 days, oxygen requirements or death.</p> <p><strong>Results</strong>: A total of 116 HRV/ENT, 102 RSV, 99 FLU and 64 other common respiratory viruses were identified. Children with single HRV/ENT infections presented with significantly higher rates of underlying immunosuppressive conditions compared to those with RSV (37.9% vs 13.6%; p</p> <p><strong>Conclusions</strong>: Children with HRV/ENT had a more severe clinical course than those with RSV and FLUA/B infections and often had significant comorbidities. These findings emphasize the importance of considering HRV/ENT infection in children presenting with severe acute respiratory tract infections.</p> / Master of Science (MSc)

Le syndrome de détresse respiratoire aiguë (SDRA) est une forme de défaillance respiratoire sévère, cause majeure de mortalité (~30-45%) chez les adultes et enfants dans les unités de soins intensifs. En dépit des progrès dans la prise en charge du patient, il n’existe à ce jour aucun traitement curatif pharmacologique efficace. Le SDRA peut se développer à la suite d’une atteinte pulmonaire directe (ex. pneumonie) ou indirecte (ex. septicémie) dont les principales caractéristiques sont des lésions épithéliales alvéolaires et endothéliales vasculaires, le développement d’un oedème pulmonaire et une réponse inflammatoire exacerbée durant la phase aiguë exsudative. La résolution de ces paramètres est critique afin d’éviter l’établissement irréversible de fibrose, entraînant une défaillance respiratoire. Le caractère hétérogène du SDRA et l’implication d’une multitude de mécanismes lésionnels rendent le développement de nouvelles thérapies plus difficile. Nous avons posé l’hypothèse que la restauration de l’intégrité épithéliale, en parallèle de la résolution de l’inflammation et la résorption de l’oedème, est critique pour la résolution de la phase exsudative du SDRA. Nous avons donc postulé que des stratégies combinant des effets bénéfiques sur la clairance liquidienne et proréparatrice constitueraient une voie intéressante pour la restauration de l’intégrité fonctionnelle de l’épithélium alvéolaire. L’objectif général de mon projet de doctorat était donc d’évaluer différentes stratégies, ciblant 1) l’inflammation, 2) le canal sodique ENaC impliqué dans la clairance liquidienne et 3) les canaux potassiques ayant un rôle pro-réparateur, avec des modèles complémentaires in vivo de lésions aiguës induites, mimant des paramètres de SDRA. Nous pensons que cette étude aura apporté de nouvelles connaissances sur la physiopathologie du SDRA et les mécanismes de résolution des paramètres caractéristiques de ce syndrome. Mon projet met particulièrement en lumière que de cibler une seule composante telle que l’inflammation ou la clairance liquidienne n’est pas suffisante et que des composés permettant de restaurer l’intégrité fonctionnelle alvéolaire sont nécessaires. / Acute respiratory distress syndrome (ARDS) is a severe form of respiratory failure, a leading cause of death (~30-45%) among adults and children in intensive care units. Despite advances in the management and care of ARDS patients, there is currently no effective curative pharmacological treatment. The ARDS can develop following a direct (e.g. pneumonia) or indirect (e.g. sepsis) lung injury, the main features of which are alveolar epithelial and endothelial vascular injury, the development of pulmonary edema, and an exacerbated inflammatory response during the exsudative acute phase. The resolution of these parameters is critical to avoid the irreversible establishment of fibrosis leading to respiratory failure. The heterogeneous nature of ARDS and the involvement of various lesional mechanisms complicate the development of new therapeutic strategies. We hypothesized that the epithelial restoration, in parallel with inflammatory resolution and edema resorption, is critical for the resolution of the acute exsudative phase of ARDS. Therefore, we postulated that strategies combining beneficial effects on fluid clearance and pro repair may be an interesting way to restore the functional integrity of the alveolar epithelium. The general objective of my PhD project was to evaluate different strategies targeting 1) the inflammation, 2) the sodium channel ENaC involved in fluid clearance, and 3) potassium channels playing pro repair role, using complementary in vivo models of acute lung injury mimicking ARDS parameters. We believe that these studies have provided new insight on the pathophysiology of ARDS and the mechanisms of resolution of the characteristic parameters of this syndrome. In particular, my project highlights that focusing on a single component such as inflammation or fluid clearance is not sufficient and that compounds will restore functional alveolar integrity are needed.